Cogstate Limited revised earnings guidance for the fiscal year ending 30 June 2023. For the year, revenue expected to be approximately 6% to 9% below fiscal year 2022; EBIT is expected to be in the range of 6% to 8% of revenue (4 November 2022 guidance of 20% to 24%).
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
1.4 AUD | +2.19% | +2.19% | -3.11% |
Apr. 01 | Cogstate Amends License Agreement with Eisai for Alzheimer’s Treatment | MT |
Feb. 22 | Cogstate's Fiscal H1 Attributable Profit Jumps, Revenue Rises 3%; Shares Decline 8% | MT |
EPS Revisions
Quarterly revenue - Rate of surprise
1st Jan change | Capi. | |
---|---|---|
-3.11% | 158M | |
+25.69% | 47.86B | |
+46.90% | 41.42B | |
-3.46% | 40.66B | |
-6.20% | 28.92B | |
+9.17% | 25.55B | |
-20.42% | 19.27B | |
+0.17% | 12.15B | |
+28.07% | 12.14B | |
-1.24% | 11.99B |
- Stock Market
- Equities
- CGS Stock
- News Cogstate Limited
- Cogstate Limited Revises Earnings Guidance for the Fiscal Year Ending 30 June 2023